BACKGROUND: Hypertension and associated chronic diseases impose enormous and growing health and economic burdens worldwide. The objective of this study was to investigate the cost-effectiveness (CE) of a hypertension control program in China. METHODS: We collected information on program costs and health outcomes in three community health centers over a 1-year period. The participants were 4902 people with hypertension (systolic blood pressure [SBP] ≥140 mm Hgand/or diastolic blood pressure [DBP] ≥90 mm Hg, or on hypertension medication) aged 18 years and older. The SBP and DBP changes in the populations were estimated from a random sample of 818 participants by conducting face-to-face interviews and physical examinations. We derived CE measures based on the costs and effects on health outcomes. FINDINGS: The total cost of implementing the intervention was Renminbi (RMB) 240 772 yuan (US$35 252), or 49 yuan (US$7.17) per participant in 2009. On average, SBP decreased from 143 to 131 mm Hg (P < .001) and DBP decreased from 84 to 78 mm Hg (P < .001), the SBP decreases ranged from 7.6 to 17.8 mm Hg and DBP decreases ranged from 3.9 to 8.3 mm Hg. CE ratios ranged from RMB 3.6 to 5.0 yuan (US$0.53-US$0.73) per person per mm HgSBP decrease, and from RMB 6.3 to 9.7 yuan (US$0.92-US$1.42) per person per mm HgDBP decrease. INTERPRETATION: Per capita costs varied widely across the communities, as did changes in SBP and DBP, but CE was similar. The findings suggest (a) a positive correlation between per capita costs and program effectiveness, (b) differences in intervention levels, and (c) differences in health status. CE results could be helpful to policy makers in making resource allocation decisions.
RCT Entities:
BACKGROUND:Hypertension and associated chronic diseases impose enormous and growing health and economic burdens worldwide. The objective of this study was to investigate the cost-effectiveness (CE) of a hypertension control program in China. METHODS: We collected information on program costs and health outcomes in three community health centers over a 1-year period. The participants were 4902 people with hypertension (systolic blood pressure [SBP] ≥140 mm Hg and/or diastolic blood pressure [DBP] ≥90 mm Hg, or on hypertension medication) aged 18 years and older. The SBP and DBP changes in the populations were estimated from a random sample of 818 participants by conducting face-to-face interviews and physical examinations. We derived CE measures based on the costs and effects on health outcomes. FINDINGS: The total cost of implementing the intervention was Renminbi (RMB) 240 772 yuan (US$35 252), or 49 yuan (US$7.17) per participant in 2009. On average, SBP decreased from 143 to 131 mm Hg (P < .001) and DBP decreased from 84 to 78 mm Hg (P < .001), the SBP decreases ranged from 7.6 to 17.8 mm Hg and DBP decreases ranged from 3.9 to 8.3 mm Hg. CE ratios ranged from RMB 3.6 to 5.0 yuan (US$0.53-US$0.73) per person per mm Hg SBP decrease, and from RMB 6.3 to 9.7 yuan (US$0.92-US$1.42) per person per mm Hg DBP decrease. INTERPRETATION: Per capita costs varied widely across the communities, as did changes in SBP and DBP, but CE was similar. The findings suggest (a) a positive correlation between per capita costs and program effectiveness, (b) differences in intervention levels, and (c) differences in health status. CE results could be helpful to policy makers in making resource allocation decisions.
Authors: Gustavo C Rodriguez-Roca; Francisco J Alonso-Moreno; Almudena Garcia-Jimenez; Alvaro Hidalgo-Vega; Jose L Llisterri-Caro; Vivencio Barrios-Alonso; Antonio Segura-Fragoso; Elvira Clemente-Lirola; Susana Estepa-Jorge; Yolanda Delgado-Cejudo; Jose M Lopez-Abuin Journal: Blood Press Date: 2006 Impact factor: 2.835
Authors: Katharina Wolf-Maier; Richard S Cooper; José R Banegas; Simona Giampaoli; Hans-Werner Hense; Michel Joffres; Mika Kastarinen; Neil Poulter; Paola Primatesta; Fernando Rodríguez-Artalejo; Birgitta Stegmayr; Michael Thamm; Jaakko Tuomilehto; Diego Vanuzzo; Fenicia Vescio Journal: JAMA Date: 2003-05-14 Impact factor: 56.272
Authors: Danielle E M Brunenberg; Gwenn E C Wetzels; Patricia J Nelemans; Carmen D Dirksen; Johan L Severens; Henri E J H Stoffers; Jan S A G Schouten; Martin H Prins; Peter W de Leeuw; Manuela A Joore Journal: Pharmacoeconomics Date: 2007 Impact factor: 4.558
Authors: Kang-Ju Son; Hyo-Rim Son; Bohyeun Park; Hee-Ja Kim; Chun-Bae Kim Journal: Int J Environ Res Public Health Date: 2019-02-28 Impact factor: 3.390
Authors: Dongfeng Gu; Jiang He; Pamela G Coxson; Petra W Rasmussen; Chen Huang; Anusorn Thanataveerat; Keane Y Tzong; Juyang Xiong; Miao Wang; Dong Zhao; Lee Goldman; Andrew E Moran Journal: PLoS Med Date: 2015-08-04 Impact factor: 11.069
Authors: Elizabeth D Brouwer; David Watkins; Zachary Olson; Jane Goett; Rachel Nugent; Carol Levin Journal: BMC Public Health Date: 2015-11-26 Impact factor: 3.295
Authors: Deliana Kostova; Garrison Spencer; Andrew E Moran; Laura K Cobb; Muhammad Jami Husain; Biplab Kumar Datta; Kunihiro Matsushita; Rachel Nugent Journal: BMJ Glob Health Date: 2020-09-09